VACCINEX INC
VCNX Real Time Price USDRecent trades of VCNX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in VCNX holdings by institutional investors
Quarterly net insider trading by VCNX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
VCNX Estimated quarterly lobbying spending
VCNX Revenue by Segment or Geography
New VCNX patent grants
-
Patent Title: Use of semaphorin-4d antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis Aug. 27, 2024
-
Patent Title: Human anti-semaphorin 4d antibody Jun. 11, 2024
-
Patent Title: Anti-cd100 antibodies and methods for using the same Jun. 11, 2024
-
Patent Title: Anti-cxcl13 antibodies and methods of using the same May. 14, 2024
-
Patent Title: Integral membrane protein display on poxvirus extracellular enveloped virions May. 07, 2024
-
Patent Title: Anti-ccr8 antibodies and uses thereof Jan. 02, 2024
-
Patent Title: Use of semaphorin-4d binding molecules for the treatment of rett syndrome Mar. 07, 2023
-
Patent Title: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent Feb. 07, 2023
-
Patent Title: Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability Dec. 27, 2022
-
Patent Title: Human anti-semaphorin 4d antibody Aug. 30, 2022
-
Patent Title: Anti-cd100 antibodies and methods for using the same Mar. 15, 2022
-
Patent Title: Use of semaphorin-4d inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases Aug. 03, 2021
-
Patent Title: Integral membrane protein display on poxvirus extracellular enveloped virions Dec. 22, 2020
-
Patent Title: Polynucleotides encoding anti-cxcl13 antibodies Nov. 10, 2020
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Oct. 13, 2020
-
Patent Title: Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit May. 26, 2020
-
Patent Title: Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells May. 05, 2020
-
Patent Title: Integral membrane protein display on poxvirus extracellular enveloped virions Mar. 03, 2020
-
Patent Title: Integral membrane protein display on poxvirus extracellular enveloped virions Feb. 04, 2020
-
Patent Title: Use of anti-semaphorin-4d antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases Jan. 07, 2020
-
Patent Title: Use of semaphorin-4d binding molecules to promote neurogenesis following stroke Dec. 03, 2019
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Aug. 20, 2019
-
Patent Title: Methods of treating multiple sclerosis using anti-cd20 antibodies May. 28, 2019
-
Patent Title: Modified glycolipids and methods of making and using the same Oct. 30, 2018
-
Patent Title: Anti-cxcl13 antibodies and methods of using the same May. 08, 2018
-
Patent Title: Methods for the treatment of b cell-mediated inflammatory diseases Feb. 13, 2018
-
Patent Title: Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4d to increase tumor infiltrating leukocyte frequency Nov. 28, 2017
-
Patent Title: Targeted cd1d molecules Nov. 07, 2017
-
Patent Title: Methods for increasing immunoglobulin a levels Oct. 17, 2017
-
Patent Title: Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus Jul. 18, 2017
-
Patent Title: Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunits Jul. 11, 2017
-
Patent Title: Anti-cd100 neutralizing antibodies and methods of using the same Jun. 13, 2017
-
Patent Title: Anti-cd100 antibodies and methods of using the same Mar. 28, 2017
-
Patent Title: Modulation of nkt cell activity with antigen-loaded cd1d molecules Mar. 28, 2017
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Mar. 21, 2017
-
Patent Title: Use of semaphorin-4d binding molecules for treatment of atherosclerosis Dec. 06, 2016
-
Patent Title: Anti-cd20 antibodies and methods of use Jul. 05, 2016
-
Patent Title: Modified glycolipids and methods of making and using the same Jun. 21, 2016
-
Patent Title: Use of semaphorin-4d binding molecules for treating neurodegenerative disorders Feb. 02, 2016
-
Patent Title: Combination of sema-4d inhibitors and immunomodulators to inhibit tumors and metastases Jan. 26, 2016
-
Patent Title: Anti-sema4d antibodies and epitopes Jul. 28, 2015
-
Patent Title: Anti-vegf antibodies and uses thereof Sep. 16, 2014
-
Patent Title: Polynucleotides encoding anti-cd100 antibodies or antigen-binding fragments thereof Aug. 26, 2014
-
Patent Title: Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis Jul. 29, 2014
-
Patent Title: Anti-c35 antibody combination therapies and methods Jan. 28, 2014
-
Patent Title: Anti-cd100 neutralizing neutralizing antibodies and methods of using the same Jul. 30, 2013
-
Patent Title: Human anti-cd100 antibodies Apr. 05, 2011
-
Patent Title: Anti-il-6 monoclonal antibodies Apr. 05, 2011
-
Patent Title: Selection of human tnfα specific antibodies Oct. 05, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to VCNX from public contracts
Recent insights relating to VCNX
Recent picks made for VCNX stock on CNBC
ETFs with the largest estimated holdings in VCNX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $VCNX stock a Buy, Sell, or Hold?
- What is the price target for $VCNX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $VCNX stock?
- Who owns the most shares of $VCNX stock?
- What funds own $VCNX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VCNX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
VACCINEX INC